◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Cytokinetics Inc (CYTK) Net Income 2006–TTM

Name: Cytokinetics Inc (CYTK) net income history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Cytokinetics Inc annual net income for fiscal TTM was -$894 million, a decrease of 13.9% from -$785 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

CYTK Annual Net Income

Net Income (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Net Income	($894M)	($785M)	($590M)	($526M)	($389M)	($215M)	($127M)	($122M)	($106M)	($128M)	$16M	($38M)	($15M)	($34M)	($42M)	($48M)	($49M)	$25M	($56M)	($49M)	($57M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CYTK Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Net Income	($199M)	($206M)	($183M)	($306M)	($134M)	($161M)	($150M)	($161M)	($143M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

AXSM Net Income — Axsome Therapeutics Inc
APGE Net Income — Apogee Therapeutics, Inc. Common Stock
KRYS Net Income — Krystal Biotech Inc
KYMR Net Income — Kymera Therapeutics Inc
ARWR Net Income — Arrowhead Pharmaceuticals Inc
PTGX Net Income — Protagonist Therapeutics Inc

More CYTK metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All CYTK financial statements → Interactive CYTK charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.